JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8696 FIIN-2

Target: FGFR

Summary: Irreversible inhibitor of FGFR

≥31.75 mg/mL
B5879 GSK2879552
1 Citation

Target: LSD

Summary: Novel and irreversible LSD1 inhibitor

insoluble in EtOH; ≥10.14 mg/mL
B1104 AZD-9291
1 Citation

Target: EGFR

Summary: Mutated forms EGFR inhibitor

≥24.98 mg/mL
B1343 Phenoxybenzamine HCl

Summary: Adrenergic receptor antagonist

insoluble in H2O; ≥17.02 mg/mL
A8882 THZ1
12 Citation

Target: Cyclin-Dependent Kinases

Summary: Covalent CDK7 inhibitor,potent and selective

≥28.3 mg/mL
B5602 GGsTop

Summary: γ-glutamyl transpeptidase (GGT) inhibitor, novel and irreversible

<6.63 mg/mL
A4509 PX 12

Target: Trx

Summary: Trx-1 inhibitor

insoluble in H2O; ≥8.75 mg/mL
A8239 CA-074 Me
7 Citation

Target: Cathepsins

Summary: Cathepsin B inhibitor

insoluble in H2O; ≥19.88 mg/mL
A2024 PD168393

Target: PDGFR|FGFR|EGFR|PKC|insulin

Summary: EGFR inhibitor
A8319 Dacomitinib (PF299804, PF299)

Target: ErbB

Summary: HER inhibitor

≥23.5 mg/mL